CD1D and neoplasm: We next evaluated the effect of different dosing intervals and continuation of dosing on tumor growth in this model (donor 3; PBMC to CCRF-CEM ratio 1:1; type 1 NKT and Vγ9Vδ2-T to T-ALL ratio 1:455 and 1:18, respectively), using two different doses of the CD1d-Vδ2 hu-bsTCE (2 mg kg−1 and 0.2 mg kg−1).